IVIG enters the central nervous system during treatment of experimental autoimmune encephalomyelitis and is localised to inflammatory lesions

[1]  H. Hartung,et al.  Intravenous immunoglobulins in the treatment of relapsing remitting multiple sclerosis - results of a retrospective multicenter observational study over five years , 2005, Multiple sclerosis.

[2]  P. Sørensen,et al.  Intravenous immunoglobulin ameliorates experimental autoimmune encephalomyelitis and reduces neuropathological abnormalities when administered prophylactically , 2005, Neurological research.

[3]  M. Filippi,et al.  MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS) , 2005, Multiple sclerosis.

[4]  P. Sørensen,et al.  Intravenous immunoglobulin treatment of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis , 2005, Journal of the Neurological Sciences.

[5]  S. Rizvi,et al.  Other therapy options and future strategies for treating patients with multiple sclerosis , 2004, Neurology.

[6]  Aaron J. Johnson,et al.  A human antibody that promotes remyelination enters the CNS and decreases lesion load as detected by T2‐weighted spinal cord MRI in a virus‐induced murine model of MS , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  A. Achiron,et al.  Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: a randomized, double-blind, placebo-controlled trial. , 2004, Archives of neurology.

[8]  C. Pozzilli,et al.  Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial , 2004, The Lancet.

[9]  M. Filippi,et al.  European study on intravenous immunoglobulin in multiple sclerosis: results of magnetization transfer magnetic resonance imaging analysis. , 2004, Archives of neurology.

[10]  K. Nicolay,et al.  Blood-brain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis: a quantitative MRI study. , 2004, Brain : a journal of neurology.

[11]  Alireza Minagar,et al.  Blood-brain barrier disruption in multiple sclerosis , 2003, Multiple sclerosis.

[12]  P. Thomas Schoenemann,et al.  Brain Size Scaling and Body Composition in Mammals , 2003, Brain, Behavior and Evolution.

[13]  P. Sørensen.  The role of intravenous immunoglobulin in the treatment of multiple sclerosis , 2003, Journal of the Neurological Sciences.

[14]  F. Fazekas,et al.  Intravenous immunoglobulin G for the treatment of relapsing–remitting multiple sclerosis: a meta‐analysis , 2002, European journal of neurology.

[15]  K. Selmaj,et al.  No difference in efficacy of two different doses of intravenous immunoglobulins in MS: clinical and MRI assessment , 2002, European journal of neurology.

[16]  S. Kaveri,et al.  Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. , 2001, The New England journal of medicine.

[17]  F. Zipp,et al.  Polyspecific immunoglobulins (IVIg) suppress proliferation of human (auto)antigen-specific T cells without inducing apoptosis , 2001, Journal of Neuroimmunology.

[18]  T. Saga,et al.  Plasma protein binding of (99m)Tc-labeled hydrazino nicotinamide derivatized polypeptides and peptides. , 2001, Nuclear medicine and biology.

[19]  Robbie Robertson,et al.  Comparison of the timing of acute blood‐brain barrier breakdown to rabbit immunoglobulin G in the cerebellum and spinal cord of mice with experimental autoimmune encephalomyelitis , 2001, The Journal of comparative neurology.

[20]  I. Cohen,et al.  Suppression of experimental autoimmune encephalomyelitis by intravenously administered polyclonal immunoglobulins. , 2000, Journal of autoimmunity.

[21]  K. Asakura,et al.  Antibody-mediated Remyelination: Relevance to Multiple Sclerosis , 2000, Multiple sclerosis.

[22]  G J Barker,et al.  The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis: a serial diffusion MRI study. , 2000, Brain : a journal of neurology.

[23]  R. Motter,et al.  Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease , 2000, Nature Medicine.

[24]  J. Parisi,et al.  Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination , 2000, Annals of neurology.

[25]  R. Gold,et al.  Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases. , 1999, Archives of neurology.

[26]  F. Debruyne,et al.  In vivo and in vitro characterizations of three 99mTc-labeled monoclonal antibody G250 preparations. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  H. Saji,et al.  Intracellular metabolic fate of radioactivity after injection of technetium-99m-labeled hydrazino nicotinamide derivatized proteins. , 1999, Bioconjugate chemistry.

[28]  G. Francis.  Intravenous immunoglobulin treatment in multiple sclerosis , 1999, Neurology.

[29]  W. Oyen,et al.  Dynamic distribution and dosimetric evaluation of human non-specific immunoglobulin G labelled with 111In or 99Tcm. , 1998, Nuclear medicine communications.

[30]  V. Perry,et al.  Loss of the tight junction proteins occludin and zonula occludens-1 from cerebral vascular endothelium during neutrophil-induced blood–brain barrier breakdown in vivo , 1998, Neuroscience.

[31]  S. Kaveri,et al.  Normal immunoglobulin G protects against experimental allergic encephalomyelitis by inducing transferable T cell unresponsiveness to myelin basic protein , 1998, European journal of immunology.

[32]  C. V. Jensen,et al.  Intravenous immunoglobulin G reduces MRI activity in relapsing multiple sclerosis , 1998, Neurology.

[33]  A. Achiron,et al.  Intravenous immunoglobulin treatment in multiple sclerosis Effect on relapses , 1998, Neurology.

[34]  S. Lacroix-Desmazes,et al.  Modulation of autoimmune responses by intravenous immunoglobulin (IVIg) , 1997, Multiple sclerosis.

[35]  G. Nahler,et al.  Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis , 1997, The Lancet.

[36]  M. Dalakas,et al.  Aseptic Meningitis Associated with High-Dose Intravenous Immunoglobulin Therapy: Frequency and Risk Factors , 1994, Annals of Internal Medicine.

[37]  L. Pitts,et al.  Immunocytochemical localization of immunoglobulins in the rat brain: Relationship to the blood‐brain barrier , 1994, The Journal of comparative neurology.

[38]  C. Koh,et al.  Neurovascular permeability and fibrin deposition in the central neuraxis of Lewis rats with cell-transferred experimental allergic encephalomyelitis in relationship to clinical and histopathological features of the disease , 1993, Journal of Neuroimmunology.

[39]  U. Andersson,et al.  Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG. , 1993, Immunology.

[40]  M. Westedt,et al.  99mTc human immunoglobulin scintigraphy--a reliable method to detect joint activity in rheumatoid arthritis. , 1992, The Journal of rheumatology.

[41]  A. Fischman,et al.  Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[42]  D. Barry,et al.  The distribution of immunoglobulins and albumin in the central nervous system in acute experimental allergic encephalomyelitis , 1986, Acta neurologica Scandinavica.

[43]  Frauke Zipp,et al.  Changes in cerebral perfusion precede plaque formation in multiple sclerosis: a longitudinal perfusion MRI study. , 2004, Brain : a journal of neurology.

[44]  F. Zipp,et al.  Regulation of self-reactive T cells by human immunoglobulins--implications for multiple sclerosis therapy. , 2003, Current pharmaceutical design.

[45]  W. Oyen,et al.  Technetium-99m labeled to human immunoglobulin G through the nicotinyl hydrazine derivative: a clinical study. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[46]  G. Nahler,et al.  Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Austrian Immunoglobulin in Multiple Sclerosis Study Group. , 1997, Lancet.